Nealon Communicators’ Lectures Honor Late NCI Employee

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 2
Volume 9
Issue 2

BETHESDA, Md-The National Cancer Institute has named a new lecture series for Eleanor Nealon, a long-time employee who died of recurrent breast cancer on Oct. 22.

BETHESDA, Md—The National Cancer Institute has named a new lecture series for Eleanor Nealon, a long-time employee who died of recurrent breast cancer on Oct. 22.

The Eleanor Nealon Extraordinary Communicators’ Lecture Series will focus on the communication of science to the public and will feature “outstanding communicators who have advanced an understanding of science through their skill in communications.” Three speakers will be selected each year, drawn from the areas of technology, business, academia, the media, and the advocacy community. Ms. Nealon was an 18-year employee of the Institute. Prior to her death, she served as director of the NCI Office of Liaison

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content